Neuropace Inc
NASDAQ:NPCE
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.9
17.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Neuropace Inc
Wall Street
Price Targets
NPCE Price Targets Summary
Neuropace Inc
According to Wall Street analysts, the average 1-year price target for
NPCE
is 16.49 USD
with a low forecast of 13.13 USD and a high forecast of 21 USD.
NPCE Last Price Targets
Neuropace Inc
The latest public price target was made on Aug 14, 2024 by
Vik Chopra
from
Wells Fargo
,
who expects
NPCE
stock to
rise by 41%
over the next 12 months.
You can read more about this price target by viewing
the article on TheFly.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Vik Chopra
Wells Fargo
|
15
USD
Upside 41% |
4 months ago
Aug 14, 2024
|
NeuroPace price target lowered to $15 from $20 at Wells Fargo
TheFly
|
|
Frank Takkinen
Lake Street
|
20
USD
Upside 87% |
7 months ago
May 23, 2024
|
NeuroPace post Q1 move 'overdone,' says Lake Street
TheFly
|
|
Larry Biegelsen
Wells Fargo
|
20
USD
Upside 87% |
9 months ago
Mar 14, 2024
|
Wells Fargo Upgrades NeuroPace Inc (NPCE) to Overweight
StreetInsider
|
|
Ross Osborn
Cantor Fitzgerald
|
11
USD
Upside 3% |
1 year ago
Nov 10, 2023
|
Epilepsy-Focused MedTech NeuroPace Has Attractive Entry Point, Competitive Position
Benzinga
|
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is NPCE's stock price target?
Price Target
16.49
USD
According to Wall Street analysts, the average 1-year price target for
NPCE
is 16.49 USD
with a low forecast of 13.13 USD and a high forecast of 21 USD.
What is Neuropace Inc's Revenue forecast?
Projected CAGR
25%
For the last 3 years the
compound annual growth rate for
Neuropace Inc's revenue is
17%.
The projected
CAGR
for the next 4 years is
25%.
You don't have any saved screeners yet
